Fig. 2: Biomarker predicted tumour sensitivity to E7449 versus clinical outcome (ORR). | British Journal of Cancer

Fig. 2: Biomarker predicted tumour sensitivity to E7449 versus clinical outcome (ORR).

From: First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor

Fig. 2

The prediction score was corrected for differences in dose by multiplying with the dose (50–800 mg) and dividing by 518. The grey mid-line shows the prespecified cut-off score of 50 used to divide patients into sensitive and not sensitive (a). Overall survival of the two groups of patients predicted sensitive or resistant (b).

Back to article page